Sortera Bio

The company's core business revolves around its proprietary Deep Screening platform, which addresses data scarcity for training AI models in biologics discovery. This technology facilitates the rapid identification of therapeutic candidates by collecting vast amounts of sequence and functional data simultaneously. In a single experiment, the platform can analyze hundreds of millions to as many as three billion biologics, identifying candidates with drug-like properties in days rather than months. These extensive datasets are then used to train generative AI models that can predict new, high-affinity biologic sequences for potentially superior therapeutics. Sortera Bio's business model is centered on forming strategic partnerships and collaborations with pharmaceutical companies and researchers. A key collaboration is with AstraZeneca, which leverages the Deep Screening platform to accelerate the discovery of novel biologics. The company's revenue is generated through these partnerships, which aim to develop new medicines for challenging biological targets.

In May 2024, Sortera Bio secured £7.5 million in a pre-seed financing round. The funding was led by Cambridge Innovation Capital and included participation from strategic partners AstraZeneca and BioNTech. This capital has been directed towards establishing the Deep Screening platform and advancing technology development. The company operates in the drug discovery sector from its headquarters in Cambridge, United Kingdom.